Pfizer Inc.'s Stock Analysis

Pfizer Reports First Quarter 2026 Financial Results and Guidance

Pfizer Inc. reported revenues of $14.5 billion for the first quarter of 2026, reflecting a 2% year-over-year operational growth, which excludes contributions from COVID-19 products Comirnaty and Paxlovid. Operational revenue growth was primarily driven by a 22% increase from launched and acquired products, with notable performances from Padcev, Eliquis, and oncology biosimilars. The company reaffirmed its full-year 2026 financial guidance, projecting revenues between $59.5 billion and $62.5 billion and adjusted diluted earnings per share in the range of $2.80 to $3.00.

During the first quarter, Pfizer allocated capital towards enhancing future growth, investing $2.5 billion in internal research and development and returning $2.4 billion to shareholders through dividends. The company is focused on maintaining operational efficiency and plans to continue de-levering its balance sheet. As of May 5, 2026, Pfizer has a remaining share repurchase authorization of $3.3 billion, although no share repurchases are anticipated for the year.

May 05, 2026 07:01:20

Pfizer Submits Required Signatures for SEC Compliance

Pfizer has fulfilled its obligations under the Securities Exchange Act of 1934 by signing the necessary documents. This action indicates compliance with regulatory requirements, which is essential for maintaining investor confidence and transparency.

Apr 27, 2026 17:16:36

Pfizer Reports Q4 2025 Results and 2026 Financial Guidance

Pfizer Inc. announced its financial results for the fourth quarter and full year of 2025, reporting total revenues of $62.6 billion for the year, which is a 2% decrease compared to 2024. The fourth-quarter revenues were $17.6 billion, reflecting a 3% decline year-over-year. Excluding COVID-19 product contributions, there was a 6% operational growth in 2025, driven by strong performances in various therapeutic areas, including oncology and vaccines. The company reported a diluted loss per share of $(0.29) for the fourth quarter, while adjusted diluted EPS was $0.66. Pfizer reaffirmed its full-year 2026 revenue guidance between $59.5 billion and $62.5 billion, anticipating approximately $5 billion from COVID-19 products and a negative impact of $1.5 billion from product exclusivity losses.

In 2025, Pfizer invested $10.4 billion in research and development and $8.8 billion in business development, including acquisitions. The company returned $9.8 billion to shareholders through cash dividends. For 2026, Pfizer plans to initiate around 20 pivotal trials and maintains a balanced capital allocation strategy, with no share repurchases expected for the year. The financial outlook for 2026 includes adjusted diluted EPS guidance of $2.80 to $3.00, reflecting stable margins and an anticipated higher tax rate.

Feb 03, 2026 07:01:37

Pfizer Revises 2025 Revenue and Provides 2026 Guidance

Pfizer has revised its revenue guidance for full-year 2025 to approximately $62.0 billion, down from a previous range of $61.0 to $64.0 billion. The company has reaffirmed its adjusted diluted earnings per share (EPS) guidance for 2025 while anticipating a decline in revenues from COVID-19 products and certain products losing exclusivity, which will impact future earnings.

For full-year 2026, Pfizer expects revenue to be between $59.5 and $62.5 billion and adjusted diluted EPS to range from $2.80 to $3.00. The anticipated operational revenue growth for 2026, excluding COVID-19 and products facing loss of exclusivity, is projected to be approximately 4% year-over-year. The company plans to continue investing in its pipeline and acquired assets to support long-term growth.

Dec 16, 2025 07:01:53

Pfizer Raises $5 Billion Through Public Offering of Notes

Pfizer Inc. completed a public offering totaling $5 billion, which includes various types of notes with different maturities and interest rates. The offering features Floating Rate Notes due in 2027, along with fixed-rate notes due between 2027 and 2065, with interest rates ranging from 3.875% to 5.700%. This issuance was conducted under a previously filed shelf registration statement.

The offering was facilitated through an underwriting agreement with several financial institutions, including Citigroup Global Markets and J.P. Morgan Securities. The legal validity of the notes is also being confirmed through a legal opinion. The proceeds from this offering may impact Pfizer's financial flexibility and capital structure.

Nov 21, 2025 16:16:49

Pfizer Completes Acquisition of Metsera for $7 Billion

On November 13, 2025, Pfizer Inc. finalized its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. Under the terms of the agreement, Metsera's shareholders will receive $65.60 in cash for each share of common stock they hold at closing.

In addition to the cash payment, Metsera's shareholders are entitled to a non-transferable contingent value right, which could yield additional payments of up to $20.65 per share. These payments are contingent on the achievement of specific milestones, including the initiation of a Phase 3 clinical trial and FDA approvals for Metsera's products.

Nov 13, 2025 15:33:11

Pfizer Reports Q3 2025 Results and Adjusted EPS Guidance Update

Pfizer Inc. reported third-quarter 2025 revenues of $16.7 billion, reflecting a 7% operational decline year-over-year, primarily due to decreased COVID-19 product revenues. The company reaffirmed its full-year revenue guidance of $61.0 to $64.0 billion while raising and narrowing its adjusted diluted EPS guidance to a range of $3.00 to $3.15 from a previous range of $2.90 to $3.10. The adjustments in EPS guidance are based on solid year-to-date performance, ongoing cost improvement initiatives, and an improved effective tax rate.

In the third quarter, Pfizer's operational revenue growth was driven by its non-COVID portfolio, particularly strong performances from products like Eliquis and Vyndaqel. However, significant declines in Paxlovid and Comirnaty sales were noted due to lower COVID-19 infection rates and a narrower vaccination recommendation. The company is also on track to achieve approximately $7.2 billion in net cost savings from previously announced initiatives, contributing to productivity gains and operating margin expansion.

Nov 04, 2025 07:00:28

Pfizer Reports Q2 2025 Financial Results and Guidance Update

Pfizer Inc. reported second-quarter 2025 revenues of $14.7 billion, marking a 10% operational growth year-over-year. The company reaffirmed its 2025 revenue guidance between $61.0 and $64.0 billion while raising its adjusted diluted earnings per share (EPS) guidance by $0.10, now estimated to be between $2.90 and $3.10. Key revenue drivers included significant increases in sales from products like Vyndaqel, Comirnaty, and Paxlovid, despite challenges from higher manufacturer discounts due to the Inflation Reduction Act.

In terms of cost management, Pfizer is on track to achieve approximately $7.2 billion in net cost savings from ongoing initiatives by the end of 2027. The company has allocated capital towards research and development, investing $4.7 billion in the first half of 2025, while returning $4.9 billion to shareholders through dividends. Pfizer's effective tax rate decreased due to a favorable jurisdictional mix, contributing positively to its financial performance in the quarter.

Aug 05, 2025 07:08:22

Pfizer Reports Q1 2025 Results, Reaffirms Financial Guidance

Pfizer Inc. reported first-quarter 2025 revenues of $13.7 billion, a decrease of 8% compared to the same period last year. The company achieved a reported diluted EPS of $0.52 and an adjusted diluted EPS of $0.92, reflecting a 12% increase in adjusted income year-over-year. Pfizer is on track to meet its cost savings targets, expecting approximately $4.5 billion in net savings by the end of 2025, with additional savings anticipated through 2027. The company reaffirmed its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion and adjusted diluted EPS in the range of $2.80 to $3.00, excluding potential impacts from future tariffs and trade policies.

In terms of product performance, Pfizer experienced a significant decline in Paxlovid revenues, down 75% year-over-year, largely due to decreased COVID-19 infections. However, growth was noted in other product categories, such as the Vyndaqel family and Comirnaty, which saw operational increases of 33% and 62%, respectively. The company also announced notable developments in its product pipeline, including the expansion of the RSV vaccine indication and positive results from various clinical trials. Additionally, Pfizer completed a significant sale of its investment in Haleon, generating approximately $3.3 billion in net cash proceeds.

Apr 29, 2025 08:02:49

Pfizer Reports $63.6 Billion Revenue for Full-Year 2024

Pfizer Inc. announced its financial results for the full year 2024, reporting revenues of $63.6 billion, which reflects a 7% operational growth compared to the previous year. Notably, revenues from non-COVID products grew by 12%, and the company achieved significant cost savings of approximately $4 billion through its ongoing cost realignment program. Additionally, fourth-quarter revenues reached $17.8 billion, marking a 22% year-over-year operational growth, driven by robust sales from various products including the legacy Seagen portfolio and Vyndaqel family.

However, the company faced challenges with a significant decline in revenues from Comirnaty, which decreased by 38% due to fewer COVID-19 vaccinations. The fourth-quarter also saw a reported diluted EPS of $0.07, a notable improvement from a loss in the prior year, but still reflects the impact of a $3.5 billion revenue reversal related to Paxlovid sales. Furthermore, the company reported a $2.9 billion non-cash impairment charge in the fourth quarter, indicating difficulties in its product pipeline and potential future revenue streams.

Feb 04, 2025 08:11:20